Announcements Trials
Browse Landscape

Phase

Phase NA 134Phase 2 132Phase 1 59Phase 1/2 38Phase 3 25Phase EARLY_PHASE1 21Phase 4 12Phase 2/3 4

Status

Completed 48Unknown 37Recruiting 17Terminated 14Active not recruiting 11Not yet recruiting 7Withdrawn 4Suspended 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 15Head & Neck 5Breast 4Other hematologic neoplasm 3Lymphoid 3Genitourinary 3Dermatologic 3Sarcoma 2Gynecologic 2CNS 2Thoracic 1Other neoplasm 1Myeloid 1

Conditions

Breast Neoplasms 4Urinary Incontinence 1Orgasm 1Medication Adherence 1Inflammatory Breast Neoplasms 1

Interventions

taxane 1bavituximab 1Taxes 1Paclitaxel 1Neoadjuvant Therapy 1Motivational Interviewing 1Docetaxel 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2/3 × Withdrawn × Breast × Clear all
NCT02883361 2024-12-05

MI for AIs

University of Calgary

Phase 2/3 Withdrawn
Breast

Breast Neoplasms, Medication Adherence

NCT00397761 2021-02-17

Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer

Medstar Health Research Institute

Phase 2/3 Withdrawn
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT01724242 2017-11-28

Vaginal DHEA for Women After Breast Cancer

Hadassah Medical Organization

Phase 2/3 Withdrawn
Breast

Breast Neoplasms, Orgasm, Urinary Incontinence

NCT02651610 2017-07-11

Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer

Peregrine Pharmaceuticals

Phase 2/3 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡